Sigma-1 receptor agonists - Pipeline Insight, 2022
![](/report_cover/8047/sigma-1-receptor-agonists-pipeline-insight-2022_en.gif)
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “Sigma-1 receptor agonists - Pipeline Insight, 2022” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Sigma-1 receptor agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Sigma-1 receptor agonists: Overview
Sigma-1 receptor (S1R) is a multi-functional, ligand-operated protein situated in endoplasmic reticulum (ER) membranes and changes in its function and/or expression have been associated with various neurological disorders including amyotrophic lateral sclerosis/frontotemporal dementia, Alzheimer’s (AD) and Huntington’s diseases (HD). Sigma-1 receptor is a 223 amino acid-long transmembrane protein residing in the ER membrane. S1R preferentially localizes to the specific microdomains of the ER called mitochondrial-associated membranes (MAM), where it can regulate InsP3R-dependent calcium flux from the ER to mitochondria, lipid dynamics, MAM stability, and the ER stress response. S1R agonists are broadly neuroprotective and this is achieved through a diversity of S1R-mediated signaling functions that are generally pro-survival and anti-apoptotic.
Report Highlights
This segment of the Sigma-1 receptor agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sigma-1 receptor agonists Emerging Drugs
Further product details are provided in the report……..
Sigma-1 receptor agonists: Therapeutic Assessment
This segment of the report provides insights about the different Sigma-1 receptor agonists drugs segregated based on following parameters that define the scope of the report, such as:
Sigma-1 receptor agonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Sigma-1 receptor agonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sigma-1 receptor agonists drugs.
Sigma-1 receptor agonists Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Sigma-1 receptor agonists - Pipeline Insight, 2022” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Sigma-1 receptor agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Sigma-1 receptor agonists: Overview
Sigma-1 receptor (S1R) is a multi-functional, ligand-operated protein situated in endoplasmic reticulum (ER) membranes and changes in its function and/or expression have been associated with various neurological disorders including amyotrophic lateral sclerosis/frontotemporal dementia, Alzheimer’s (AD) and Huntington’s diseases (HD). Sigma-1 receptor is a 223 amino acid-long transmembrane protein residing in the ER membrane. S1R preferentially localizes to the specific microdomains of the ER called mitochondrial-associated membranes (MAM), where it can regulate InsP3R-dependent calcium flux from the ER to mitochondria, lipid dynamics, MAM stability, and the ER stress response. S1R agonists are broadly neuroprotective and this is achieved through a diversity of S1R-mediated signaling functions that are generally pro-survival and anti-apoptotic.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Sigma-1 receptor agonists R&D. The therapies under development are focused on novel approaches for Sigma-1 receptor agonists.
This segment of the Sigma-1 receptor agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sigma-1 receptor agonists Emerging Drugs
- Fenfluramine: Zogenix
- Pridopidine: Prilenia Therapeutics
Further product details are provided in the report……..
Sigma-1 receptor agonists: Therapeutic Assessment
This segment of the report provides insights about the different Sigma-1 receptor agonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Sigma-1 receptor agonists
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Sigma-1 receptor agonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Sigma-1 receptor agonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sigma-1 receptor agonists drugs.
Sigma-1 receptor agonists Report Insights
- Sigma-1 receptor agonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Sigma-1 receptor agonists drugs?
- How many Sigma-1 receptor agonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sigma-1 receptor agonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sigma-1 receptor agonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Sigma-1 receptor agonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Zogenix
- Prilenia Therapeutics
- Algernon Pharmaceuticals
- Anavex Life Sciences
- Axsome Therapeutics
- Proximagen
- Avanir Pharmaceuticals
- Fenfluramine
- Pridopidine
- NP 120
- ANA001-HCl
- AXS-05
- ANAVEX 3-71
- PRX-00023
- AVP-786
- ANAVEX 2-73/DPZ
Introduction
Executive Summary
Sigma-1 receptor agonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Sigma-1 receptor agonists – DelveInsight’s Analytical Perspective
Late Stage Products (Preregistration)
Comparative Analysis
Fenfluramine: Zogenix
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Ifenprodil: Algernon Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ANAVEX 3-71: Anavex Life Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Sigma-1 receptor agonists Key Companies
Sigma-1 receptor agonists Key Products
Sigma-1 receptor agonists- Unmet Needs
Sigma-1 receptor agonists- Market Drivers and Barriers
Sigma-1 receptor agonists- Future Perspectives and Conclusion
Sigma-1 receptor agonists Analyst Views
Sigma-1 receptor agonists Key Companies
Appendix
Executive Summary
Sigma-1 receptor agonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Sigma-1 receptor agonists – DelveInsight’s Analytical Perspective
Late Stage Products (Preregistration)
Comparative Analysis
Fenfluramine: Zogenix
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Ifenprodil: Algernon Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ANAVEX 3-71: Anavex Life Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Sigma-1 receptor agonists Key Companies
Sigma-1 receptor agonists Key Products
Sigma-1 receptor agonists- Unmet Needs
Sigma-1 receptor agonists- Market Drivers and Barriers
Sigma-1 receptor agonists- Future Perspectives and Conclusion
Sigma-1 receptor agonists Analyst Views
Sigma-1 receptor agonists Key Companies
Appendix